Bimzelx reaches public drug plans in all 10 provinces for two arthritis indications, UCB says
UCB says Manitoba completed provincial coverage for eligible adults with active psoriatic arthritis or ankylosing spondylitis. Each plan sets its own criteria.
In this article & details
UCB Canada said on Nov. 17 that Bimzelx (bimekizumab) is now listed by public drug plans in all 10 provinces for eligible adults with active psoriatic arthritis or active ankylosing spondylitis. The company said Manitoba was the last province to add coverage for those two indications.
Most provincial plans already listed the biologic for those conditions in 2025, according to UCB. The announcement puts the Manitoba listing in national context. UCB also reported coverage through federal programs. Eligibility and the approval process vary with the plan.
Manitoba lists Bimzelx through Exception Drug Status
Manitoba’s Exception Drug Status criteria list bimekizumab for active psoriatic arthritis and active ankylosing spondylitis in patients who meet the province’s requirements. The criteria differ by diagnosis and include requirements related to previous treatment. The province also lists Bimzelx for severe plaque psoriasis under separate criteria.
Other jurisdictions apply their own listing terms. Quebec, for example, identifies Bimzelx as an exceptional medication for the two arthritis indications. A provincial listing establishes a route to public funding for people who meet that plan’s criteria.
Patient group welcomes another funded treatment option
Cheryl Koehn, president of Arthritis Consumer Experts, welcomed Manitoba’s decision in UCB’s announcement and called for timely access to effective treatment. The newly reported provincial coverage milestone concerns two indications. A claim still depends on the patient’s drug plan, the diagnosis and the applicable authorization.
References
- Bimzelx gains broad public reimbursement coverage in Canada — UCB Canada, Manufacturer announcement, Nov. 17, 2026
- Exception Drug Status — Manitoba Health, Bimekizumab coverage criteria
- Bimzelx coverage for psoriatic arthritis and ankylosing spondylitis — Régie de l’assurance maladie du Québec, Québec public plan entry